Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study

Substantially all planned REO 033 clinical sites are now activated, with multiple patients currently on studyCompany expects to have sufficient Part A data to provide an interim clinical update by year-end 2026FDA alignment provides potential path to accelerated approval based on objective response…